

Tumor treating Fields as the novel standard of care for GBM Fourth Modality on Cancer Therapy

Clinical training and education

May 9TH 2019

LIPSSET AUDITORIUM BLDG 10
NATIONAL INSTITUTE OF HEALTH

CLINICAL CENTER

*9000 Rockville Avenue
Bethesda, Maryland
USA*

- | | |
|------------|--|
| May 9th | Opening ceremony Remarks |
| 8:00-8:30 | Dr. Robert Lembo, Director Office of Clinical Education and training
Clinical Center NIH. |
| 8:30-9:00 | I)Introduction Tumor Treating Fields
Efficacy of treating electrical fields therapy to treat brain tumors
Dr. Patrick Wen
Past President Society of Neuro-Oncology
Professor of Neurology, Harvard Medical School
Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute |
| 9:00-9:30 | Application of tumor treating fields for newly diagnosed
glioblastoma: understanding of nationwide practice patterns
Dr. Jerry Daboin
Department of Radiation Medicine Oregon Health & Science University
Portland USA |
| 9:30-10:00 | TTF efficacy over temozolomide for GBM EF12 trial
Dr. Suriya
Neurosurgeon, Head of Neuro-Oncology Tufts
Medical Center , Boston MA |

- 10:05-10:15** **Coffee break**
- 10:15-10:45** **Ependymomas and Spinal Tumors: Current Treatment Strategies and Limitations**
 Dr. Larry Lo
 Professor, Spine Neurosurgery Johns Hopkins SOM
- 10:45-11:00** **Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma**
 Dr. Andreas Hottinger
 Head of Neuro-Oncology
 Centre Hospitalaire Laussane Switzerland
- 11:00-11:45** **Development of Multicentric trial using TTF for GBM**
 Dr. Jai Grewal and Eilon Kirston
 Haifa University Israel
- 11:45-12:15** **Tumor treating fields mechanism of action**
 Dr. Moshe Giladi
 Director of Technology
 Novocure, Haifa Israel
- 12:15-12:40** **The future of TTFields in GBM and beyond**
 Dr. Uri Weinberg
 VP Clinical Development, Novocure USA
- 12:40-13:00** **Molecular markers, and marker driven studies in GBM, and what we can learn to understand mechanisms of response and resistance**
 Prof Monika E. Hegi, PhD
 Laboratory of Brain Tumor Biology and Genetics (LBGT)
 Neurosurgery & Neuroscience Research Center
 Department of Clinical Neurosciences
 Switzerland
- Chair: TBD Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research FDA**

- 13:00-13:30** **New modalities to image brain tumors at the Clinical Center**
Dr. John Butman
Head Neuro-Radiology Unit
Clinical Center NIH
- 13:30- 14:00** **TTF as integrative solution for treating GBM patients**
Dr. Joshua Palmer
Department of Neuro-Oncology, The Ohio State University, Columbus.
- 14:00- 14:30** **Stereotactic Radiosurgery and TTF on recurrent GBM**
Dr. Young Kwok
Maryland Proton Center and Radiation Oncology
- 14:30- 15:00** **Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas**
Dr. Chris Straub
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), 81675, Munich, Germany.
- 15:30- 16:00** **TTF therapy on Pancreatic Adenocarcinoma and Lung Cancer**
Dr. Hani Babiker
Clinical Trials Unit
University of Arizona Cancer Center
- 16:00- 16:30** **MRI analysis on 7T: Biomarkers on effectiveness for TTF therapy**
Dr. Mohed
Neuro-Radiology Department
Penn University
- 16:30- 17:00** **Round table discussion Speakers**

